Videos

The NETRF lends funding to help discover new and emerging treatment options in neuroendocrine tumors, according to Anna Greene, PhD.

Anna Greene, PhD, spoke about how this under-studied disease needs increased funding and more awareness.

Panelists discuss how the COCOON trial demonstrated that enhanced dermatologic management significantly reduced grade 2 or higher skin-related adverse events (38% vs 76%) compared with standard of care for patients receiving amivantamab plus lazertinib.

Panelists discuss how amivantamab plus lazertinib therapy for EGFR-mutant non–small cell lung cancer has shown promising survival data while highlighting the importance of managing adverse events for improved quality of life.

Extravasation with beta emitters may elicit more drastic adverse effects due to their higher radiation dose.

Increasing the use of patient-reported outcomes may ensure that practitioners can fully ascertain the impact of treatment for rare lymphomas.

Photographic and written documentation can help providers recognize inflammatory breast cancer symptoms across diverse populations.

The use of guideline-concordant care in breast cancer appears to be more common in White populations than Black populations.

Panelists discuss how rebiopsy and CD20 reassessment at suspected progression of follicular lymphoma after second-line therapy are critical for detecting histologic transformation, evaluating changes in disease biology, and informing the selection of appropriate third-line treatment strategies.

Panelists discuss how recognizing disease heterogeneity and monitoring for clinical indicators of progression in relapsed/refractory follicular lymphoma (R/R FL) are essential for guiding timely and individualized third-line treatment decisions that optimize patient outcomes.

Panelists discuss how the efficacy data from SWOG 80702 demonstrated that shortened duration of adjuvant chemotherapy (3 months vs 6 months) yielded comparable survival outcomes while significantly reducing treatment-related toxicities, challenging previous standard-of-care approaches for patients with stage III colon cancer.

Panelists discuss how SWOG 80702, a large-scale randomized clinical trial, employed a robust factorial design with clearly defined efficacy end points, including disease-free and overall survival, while enrolling a diverse patient population with stage III colon cancer to evaluate optimal adjuvant therapy duration and the impact of celecoxib.

Retrospective and real-world registry studies may be necessary to guide clinical decision-making for rarer lymphomas with insufficient prospective data.

Extravasation results in exposing healthy tissue to radiation, which can be highly dosed depending on the isotope used for treatment.

Panelists discuss how recognizing the distinct histological patterns and the hallmark loss of INI1 expression in epithelioid sarcoma (ES) can enhance diagnostic precision, inform prognosis, and guide emerging targeted therapeutic strategies.

Panelists discuss how understanding the epidemiology, clinical presentation, and metastatic patterns of epithelioid sarcoma (ES) can support earlier recognition, accurate diagnosis, and more effective multidisciplinary management of this rare and aggressive soft tissue tumor.

Panelists discuss how PSMA PET imaging is increasingly utilized to assess treatment response in prostate cancer, offering superior accuracy over PSA monitoring alone. Incorporating PSMA PET into clinical practice involves considering factors such as timing post treatment and the specific clinical scenario. For instance, studies have demonstrated that PSMA PET/CT can detect intraprostatic and metastatic lesions even at very low PSA levels during treatment monitoring.

Panelists discuss how the growing role of combination therapies in EGFR-mutated non–small cell lung cancer (NSCLC) influences the choice between the MARIPOSA and FLAURA2 trials, considering overall survival data, multidisciplinary implementation, patient education, and their impact on first-line prescribing decisions.

Panelists discuss how both chemotherapy-free and chemotherapy-containing combinations offer valuable treatment options for first-line EGFR-mutated non–small cell lung cancer (NSCLC) patients, with considerations including survival benefits, brain metastasis concerns, adverse effect profiles, and the evolution toward personalized treatment selection rather than viewing either approach as universally superior.

Panelists discuss how, PSMA PET imaging significantly enhances surgical decision-making in prostate cancer by precisely identifying tumor location, extent, and metastatic spread with superior sensitivity compared to conventional imaging. This molecular targeting enables more accurate surgical planning, improved patient selection for radical prostatectomy versus targeted approaches, and better identification of lymph node involvement, ultimately allowing for personalized treatment strategies that maximize oncological outcomes while minimizing unnecessary interventions.

Ongoing studies seek to evaluate immunotherapy in earlier lines of therapy for patients with early-stage Hodgkin lymphoma.

Strict inclusion criteria may disproportionately exclude racial minority populations from participating in breast cancer trials.

Steven Finkelstein, MD, DABR, FACRO, spoke about the impact of the approval of 177Lu for patients with PSMA-positive mCRPC.

A paucity of prospective, well-vetted data to guide therapy in patients with rare lymphomas may result in a reliance on expert consensus guidelines.

Testing a patient’s genetics may influence decisions such as using longer courses of radiotherapy, says Rachit Kumar, MD.

Panelists discuss how minimal residual disease (MRD) status, as detected through circulating tumor DNA analysis, can guide personalized treatment decisions by identifying patients who may benefit from intensification of adjuvant therapy and those who could safely undergo de-escalation of treatment regimens.

Panelists discuss how circulating tumor DNA (ctDNA) clearance rates during and after adjuvant chemotherapy (ACT) in the BESPOKE trial provide critical insights into treatment efficacy and may serve as an early predictor of long-term patient outcomes.

Multidisciplinary collaboration may help in minimizing the treatment burden among patients with prostate cancer, according to Curtiland Deville Jr, MD.

Spatial transcriptomics and multiplex immunohistochemistry from samples may elucidate outcomes for patients who undergo surgical care for cancer.

Panelists discuss how the significant overall survival (OS) benefit demonstrated by the new combination therapy (amivantamab-lazertinib) compared with standard monotherapy makes it a preferred treatment option for most patients despite a slightly increased toxicity and time commitment.